Abstract
Nintedanib is an oral triple angiokinase inhibitor which simultaneously inhibits vascular endothelial growth factor receptors (VEGFR), platelet derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR) signalling pathways. Growing scientific evidence shows that these three different angiokinase receptors play an important role not only in angiogenesis but also in tumour growth and metastasis.
Nintedanib (Vargatef(R)) in combination with docetaxel was approved in the EU in 2014 for use by adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first line chemotherapy. The LUME-Lung 1 and LUME-Lung 2 studies demonstrated the efficacy and safety of the treatment by nintedanib.
Nintedanib (Ofev(R)) is used to treat a lung disease called idiopathic pulmonary fibrosis to slow down disease progression